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Abstract
Background A retrospective study was undertaken to define
the efficacy of both mini gastric bypass or one anastomosis
gastric bypass (MGB/OAGB) and sleeve gastrectomy (SG) in
type 2 diabetes mellitus (T2DM) remission in morbidly obese
patients (pts).
Methods Eight European centers were involved in this survey.
T2DM was preoperatively diagnosed in 313/3252 pts
(9.62 %). In 175/313 patients, 55.9 % underwent MGB/
OAGB, while in 138/313 patients, 44.1 % received SG be-
tween January 2006 and December 2014.
Results Two hundred six out of 313 (63.7 %) pts reached
1 year of follow-up. The mean body mass index (BMI) for
MGB/OAGB pts was 33.1±6.6, and the mean BMI for SG pts
was 35.9±5.9 (p<0.001). Eighty-two out of 96 (85.4 %)
MGB/OAGB pts vs. 67/110 (60.9 %) SG pts are in remission
(p<0.001). No correlation was found in the % change vs.
baseline values for hemoglobin A1c (HbA1c) and fasting
plasma glucose (FPG) in relation to BMI reduction, for both
MGB/OAGB or SG (ΔFPG 0.7 and ΔHbA1c 0.4 for MGB/
OAGB;ΔFPG 0.7 andΔHbA1c 0.1 for SG). At multivariate
analysis, high baseline HbA1c [odds ratio (OR)=0.623, 95 %
confidence interval (CI) 0.419–0.925, p=0.01], preoperative
consumption of insulin or oral antidiabetic agents (OR=
0.256, 95 % CI 0.137–0.478, p=<0.001), and T2DM duration
>10 years (OR=0.752, 95 % CI 0.512–0.976, p=0.01) were
negative predictors whereas MGB/OAGB resulted as a posi-
tive predictor (OR=3.888, 95 % CI 1.654–9.143, p=0.002) of
diabetes remission.
Conclusions A significant BMI decrease and T2DM remis-
sion unrelated from weight loss were recorded for both proce-
dures if compared to baseline values. At univariate and mul-
tivariate analyses, MGB/OAGB seems to outperform signifi-
cantly SG. Four independent variables able to influence
T2DM remission at 12 months have been identified.
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Introduction
Type 2 diabetes mellitus (T2DM) and morbid obesity are con-
ditions representing increasing public health threats. They are
associated with significant morbidity and mortality, and de-
spite lifestyle modifications and medical support, glycemic
* Mario Musella
mario.musella@unina.it
1 Department of Advanced Biomedical Sciences, BFederico II^
University, Via S. Pansini 5, Building 12, 80131 Naples, Italy
2 Leeuwarden Medical Center, Leeuwarden, The Netherlands
3 St. Franziskus Hospital, Cologne, Germany
4 Centro Hospitalar de Lisboa Central, Lisbon, Portugal
5 AORN BA. Cardarelli^, Naples, Italy
6 Clinica BCastelli^, Bergamo, Italy
7 Břeclav Hospital, Břeclav, Czech Republic
8 AORN BG. Garibaldi^, Catania, Italy
OBES SURG (2016) 26:933–940
DOI 10.1007/s11695-015-1865-6
control remains difficult to achieve in obese diabetic patients
[1]. Bariatric surgery has so far shown high efficacy in achiev-
ing T2DM long-term remission and durable weight loss [2–4],
leading the International Diabetes Federation (IDF) and the
American Diabetes Association (ADA) to suggest bariatric
surgery as an effective treatment modality in obese patients
with T2DM [5, 6].
Different laparoscopic bariatric procedures have been in-
vestigated to treat T2DM obese patients, with excellent results
in terms of weight loss and glycemic control reported for both
the biliopancreatic diversion with or without the duodenal
switch (BPD/BPD-DS) and the Roux-en-Y gastric bypass
(RYGBP) [2, 7]. Conversely, restrictive procedures such as
the sleeve gastrectomy (SG) and the laparoscopic adjustable
gastric banding (LAGB), although effective on weight loss,
seem to provide different results on T2DM remission. In fact,
while the SG presents an outcome that, in some studies, is
comparable to RYGBP [8–10], the LAGB seems to determine
a lesser impact on glucose homeostasis, achieving controver-
sial results [2, 11, 12]. The mini gastric bypass or one anasto-
mosis gastric bypass (MGB/OAGB) originated by Rutledge
in 1997 [13] is an emerging technique consisting in a simpli-
fied version of the classic RYGBP. When described, MGB/
OAGB raised severe criticism, reprised in a more recent de-
bate [14, 15], but despite such skeptical position, different
authors have reported excellent results in terms of weight loss
and resolution of obesity-related comorbidities [16], including
T2DM [17] and women obesity-related infertility [18]. To
date, MGB/OAGB has reached the status of a standard bariat-
ric procedure in Italy (http://www.sicob.org) and many other
countries [19], providing excellent results even in the long
term [20]. A recent survey endorsed by the International
Federation for the Surgery of Obesity and Metabolic
Disorders (IFSO) has reported MGB/OAGB being the most
frequently performed procedure following the more
established laparoscopic RYGBP, SG, and LAGB in
Europe and Asia/Pacific area [21]. Following the Second
International Consensus Conference on MGB/OAGB, held
in Paris in October 2013, a group of European surgeons espe-
cially experienced with both MGB/OAGB and SG agreed to
participate in a large-scale multicenter retrospective study to
compare and define the efficacy of these two procedures in
determining weight loss and T2DM remission.
Patients and Methods
Under the coordination of the pilot center located at the Uni-
versity of Naples Federico II, Italy, seven hospital bariatric
units, three from Italy and four from Germany, Netherlands,
Portugal, and Czech Republic respectively, participated in this
multicenter audit. Only the clinical records of 3252 bariatric
patients operated by MGB/OAGB or SG between January
2006 and December 2014 were retrospectively reviewed.
Criteria of inclusion in the study, according to the widely
accepted criteria from IFSO and ADA [22], were obese pa-
tients with at least 1 year of follow-up, who underwent MGB/
OAGB or SG with a body mass index (BMI) >35 kg/m2, with
an age ranging from 18 to 60 and presenting a glycosylated
hemoglobin A1c (HbA1c) level ≥6.5 % or a fasting plasma
glucose (FPG) level ≥126 mg/dL (fasting was defined as no
caloric intake for at least 8 h) or a 2-h plasma glucose level
≥200 mg/dL during an oral glucose tolerance test (OGTT) or a
patient with classic symptoms of hyperglycemia or hypergly-
cemic crisis, with a random plasma glucose level ≥200mg/dL.
Exclusion criteria included revision, reversal, or conver-
sion bariatric surgery for any reason; perioperative complica-
tions including operated patients who developed amalignancy
during follow-up; or patients lost to follow-up.
Starting from January 2014, data from all patients fulfilling
inclusion criteria were included in an electronic sheet and
returned to pilot center. Two independent reviewers collected
all charts from each center in a prospectively built database.
Data Extraction
The following data were considered:
& At baseline: patient age and sex, preoperative BMI (kg/m2),
preoperative FPG (mg/dL), preoperative HbA1c (%), dia-
betes duration in years, assumption of insulin or oral anti-
diabetic agents, antihypertensive drugs, preoperative total
and fractionated cholesterol (mg/dL), preoperative triglyc-
erides (mg/dL), lipid-lowering agent assumption, preoper-
ative blood pressure (mmHg), and type of surgical proce-
dure (MGB/OAGB or SG)
& Within the first 30 postoperative days: perioperative mor-
tality and morbidity
& At follow-up (1 year for all centers): BMI,ΔBMI, excess
weight loss rate (EWL%), FPG, HbA1c, use of insulin or
glucose-lowering agents, blood pressure (BP), antihyper-
tensive drug assumption, total and fractionated cholester-
ol, triglycerides, and lipid-lowering agent assumption
Surgical Technique
The SG standard technique, performed in all centers, followed
previously described procedures [23–25]. Vertical gastrecto-
my started from 5.5±1.5 cm proximal the pylorus with a bou-
gie size ranging from 36 to 40 French (Fr) size in all patients.
The MGB/OAGB surgery was performed by preparing a gas-
tric pouch sizing 15±2.5 cm in length and tailoring a mechan-
ical linear wide gastrojejunal anastomosis at 195±25.5 cm
from the ligament of Treitz in all patients [13, 25]. No
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single-incision laparoscopic surgery (SILS) procedures were
performed in these patients.
Outcomes
The following endpoints have been investigated:
& Primary endpoint: to define and compare the efficacy of
MGB/OAGB and SG in determining type 2 diabetes
remission according to the 2009 consensus group
criteria endorsed by the American Diabetes Association
[26]. FPG levels <126 mg/dL or HbA1c <6.5 % of at
least 1-year duration in the absence of insulin or
glucose-lowering agent administration were considered
as remission criteria.
& Secondary endpoint: to define the efficacy and the
eventual risks of both MGB/OAGB and SG in deter-
mining BMI and EWL% changes in this specific sub-
set of diabetic patients. The following were considered
as perioperative complications: pulmonary embolism
(PE), acute myocardial infarction (AMI), stroke,
intra-abdominal bleeding, gastrointestinal bleeding,
and gastrointestinal leak.
& Tertiary endpoint: to evaluate the impact of diabetes dura-
tion on the efficacy of surgical procedures.
As a complementary endpoint, the control of hypertension
and dyslipidemia, according to ADA criteria [3, 27], was also
investigated. Hypertension control is defined as systolic BP
lower than 130 mmHg and diastolic BP lower than 80 mmHg.
Definitions of dyslipidemia control include low-density lipo-
protein (LDL) lower than 100mg/dL, high-density lipoprotein
(HDL) higher than 40 mg/dL (or 50 mg/dL in men), and
triglycerides lower than 150 mg/dL. Data were reported only
for patients previously in treatment, free at control visit from
antihypertensive or lipid-lowering agent drug therapy.
Statistical Analysis
Statistical analysis was performed using the SPSS 17 system
(SPSS Inc., Chicago, IL, USA). Continuous data were
expressed as the means±SD, and categorical variables were
expressed as the% changes. To compare continuous variables,
an independent and/or paired sample t test was performed and
correlation was assessed using Pearson’s linear correlation
coefficients (r). Changes in BMI (ΔBMI) were expressed as
the % changes vs. baseline values as well. The chi-square test
was used to analyze categorical data. When the minimum
expected value was <5, Fisher’s exact test was used. To adjust
for major covariates and to generate predictions, a logistic
regression (stepwise) model was applied, with diabetes remis-
sion at 1 year, as the dependent variable, and age, gender,
baseline BMI, hypertension, hypercholesterolemia, diabetes
duration, T2DM treatment, FPG, HbA1c, surgical treatment,
BMI, and EWL% at 1 year, as independent variables. All of
the results are presented as two-tailed values with statistical
significance defined as p values <0.05.
Results
Baseline Conditions
According to the above mentioned criteria, 313/3252 T2DM
patients (9.62 %) were screened for inclusion in the study.
They were split into two groups according to the surgical
intervention performed (SG or MGB/OAGB). Baseline data
for those 206/313 patients (65.8 %) reaching 1 year of follow-
up were considered in the analysis. Table 1 defines the preop-
erative conditions for all patients. No significant differences
were observed between patients who underwentMGB/OAGB
or SG on any parameter at baseline.
Perioperative Complications
No perioperative deaths were recorded for both interventions.
Table 2 reports the morbidity rate in the two groups. All 313
patients were evaluated during the perioperative period. No
significant differences were reported between patients who
underwent MGB/OAGB or SG at this stage.
Follow-up
Of 175 patients who underwent MGB/OAGB, 112 were eli-
gible for follow-up at 1 year. Among these, 96 (85.7 %) came
for control visit. SG patients eligible for follow-up at 1 year
were 128, and among these, 110 (85.9 %) came for control
visit. The dropout rate at 1 year was of 34 patients (14.1 %)
(see Table 3). The BMI decreased significantly for both pro-
cedures if compared to baseline values (MGB from 48.3±9.2
to 33.1±6.6, p<0.001; SG from 48.1±7.8 to 35.9±5.9,
p<0.001). Noteworthy, the MGB/OAGB provided significant
BMI decrease when compared to SG at 1 year (33.1±6.6 vs.
35.9±5.9, p<0.001). This was confirmed by the observation
that MGB/OAGB compared to SG at 1 year provided both a
higher % BMI reduction vs. baseline levels (−30.9±8.93 vs.
−24.8±8.07, p<0.001) and a larger EWL% increase (64.7±
22.9 vs. 52.4±18.3, p<0.001).
Both surgical procedures achieved T2DM remission if com-
pared to baseline values (MGB from 182.5±69.7 to 104.0±
19.6, p<0.001; SG from 189.9±66.4 to 122.2±38.6,
p<0.001, for FPG; MGB from 7.6±1.5 to 5.9±1.1, p<0.001;
SG from 7.3±1.3 to 6.2±0.9, p<0.001, for HbA1c). However,
it should be noticed that MGB/OAGB provided a better per-
formance than SG at 1 year (see Table 4). If we, in fact, con-
sider patients who underwent MGB/OAGB, we have a
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remission rate from T2DM of 82/96 patients (85.4 %) for those
controlled at 1 year, while patients who underwent SG have a
remission rate of 67/110 (60.9 %) (p<0.001, see Fig. 1). Final-
ly, comparing for each intervention,MGB/OAGB or SG, the%
change vs. baseline values for HbA1c and FPG in relation to
BMI reduction, no significant correlation was found (ΔFPG
0.7 and ΔHbA1c 0.4 for MGB/OAGB; ΔFPG 0.7 and
ΔHbA1c 0.1 for SG; see Figs. 2 and 3).
Both the lipid profile and the blood pressure change, following
the two surgical procedures, have been evaluated. Table 4 shows
an improvement in lipid profile at 1 year in patients who
underwent MGB/OAGB or SG. The differences were not signif-
icant between the two procedures. The same table shows a signif-
icant decrease in both systolic and diastolic blood pressure levels at
1 year in patients who underwent MGB/OAGB vs. patients who
received SG (p<0.003 and p<0.003, respectively). After adjusting
for various clinical and demographic characteristics in a multivar-
iate logistic regression analysis, high baseline HbA1c [odds ratio
(OR)=0.623, 95 % confidence interval (CI) 0.419–0.925,
p=0.01], preoperative consumption of insulin (OR=0.256, 95 %
CI 0.137–0.478, p<0.001), and diabetes duration longer than
10 years (OR=0.752, 95 % CI 0.512–0.976, p=0.01) were found
to be negative predictors of diabetes remission at 1 year. Converse-
ly, the use of MGB/OAGB resulted as a positive predictor of
diabetes remission (OR=3.888, 95 % CI 1.654–9.143, p=0.002).
Discussion
The primary risk factor for type 2 diabetes is obesity, and 90 %
of all patients with type 2 diabetes are either overweight or
obese. The National Health and Nutrition Examination Survey
III (1988–1994) data demonstrated that the risk for chemical
diabetes is approximately 50%with a BMI greater than or equal
to 30 kg/m2 and over 90 % with a BMI of 40 kg/m2 or more
Table 1 Baseline conditions in
patients with 12 months of
follow-up according to surgical
procedure
MGB/OAGB (n=96) SG (n=110) p
Patients number 96/175 110/138
Age 48.5±8.7 49.2±9.1 0.5
Male gender 58/96 (60.4 %) 80/110 (72.7 %) 0.07
BMI 48.3±9.2 48.1±7.8 0.8
FPG 182.5±69.7 189.9±66.4 0.4
HbA1c 7.6±1.5 7.3±1.3 0.1
Diabetes duration >10 years 14/96 (14.5 %) 14/110 (12.7 %) 0.8
Oral antidiabetic 49/96 (51 %) + 46/110 (41.8 %) +
Insulin 31/96 (32.3 %) 39/110 (35.4 %)
80/96 (83.3 %) 85/110 (77.2 %) 0.3
No medication 16/96 (16.6 %) 25/110 (22.7 %) 0.3
Total cholesterol 184.9±41.2 183.1±36.9 0.7
HDL cholesterol 44.7±13.9 43.0±12.6 0.3
LDL cholesterol 119.3±40.4 120.8±38.8 0.7
Triglycerides 207.9±123.4 200.4±100.5 0.6
Blood pressure
Max (range) 136.6±16.9 140.1±18.2 0.1
Min (range) 82.4±10.8 82.5±11.0 0.9
The p value reports the eventual statistical difference in patients assuming oral antidiabetic agents and/or insulin
Table 2 Morbidity for both procedures
MGB (n=175) SG (n=138) p
Preoperative complications
Pulmonary embolism, n (%) 2 (1.1) 1 (0.7) 1.0
Myocardial infarction 0 0 –
Stroke 0 0 –
Intra-abdominal bleeding, n (%) 5a (3.6) 3 (2.1) 1.0
Gastrointestinal bleeding 0 0 –
Gastrointestinal leak 0 1 (0.7) 1.0
Others, n (%) 1 (0.5) 0 1.0
Total, n (%) 8 (4.5) 5 (3.6) 0.7
a Two patients who underwent MGB/OAGB needed surgical revision for
postoperative intra-abdominal bleeding
Table 3 Patients in follow-up at 1 year
Follow-up 1 year
Surgery MGB SG
Total patients 175 138
Eligible patients 112 128
Controlled patients, n (%) 96 (85.7) 110 (85.9)
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[17]. Since Pories’ first report in 1995 [28], a powerful body of
published evidence has shown the efficacy of bariatric surgery in
determining T2DM remission. The superiority of surgery even
in comparison to conservative treatment [29, 30] has led many
authors to investigate different procedures able to improve or
heal T2DM in both morbidly obese and mildly obese patients.
However, the mechanism by which bariatric surgery causes
T2DM remission is yet to be defined. In 2009, Cummings
reviewed the existing conjectures regarding the mechanisms
underlying diabetes remission. Based on this study, three main
hypotheses were postulated. The ghrelin hypothesis, which af-
firms that hormone release may be disturbed following RYGBP
or SG. Diminished ghrelin secretion can, in fact, decrease appe-
tite and food intake, also increasing glucose tolerance, given that
ghrelin can stimulate counter-regulatory hormones [31]. This
hypothesis remains, however, controversial. If some studies
have, in fact, shown ghrelin levels being very low following
RYGBP or SG, conversely, more recent papers have shown
hormone levels to remain unchanged following RYGBP [32].
The upper intestinal hypothesis, which states that avoiding
nutrient contact with the duodenum is somehow a key in the
process through which diabetes is improved. The basis for this
hypothesis is that unknown factors or processes from the duo-
denum influence glucose homeostasis [33]. Finally, the lower
intestinal hypothesis, which claims that the intestinal shortcuts
created by bariatric surgery, expedite delivery of ingested
nutrients and increase glucagon-like peptide-1 (GLP-1) release.
It is therefore interesting to observe how, starting from
Buchwald meta-analysis [2] to a more recent study from Den-
mark [34], it seems confirmed that only bariatric procedures as
SG, RYGBP, or BPD-DS, recalling at least one among the
three hypotheses, are able to provide an acceptable and endur-
ing T2DM remission. However, conversely, it remains unclear
how much diabetes remission, regardless of hypothesized
mechanism, can be achieved independently from weight loss.
Despite previous reports [9, 35–37], the metabolic efficacy
of SG remains an interesting issue. While several studies have
reported the efficacy of this technique, conversely, Panunzi, in
a recent meta-analysis [11], considering 4944 diabetic pa-
tients, has reduced the metabolic role of SG, reporting a
T2DM remission rate of 60 %, very similar to LAGB remis-
sion rate of 62 % and significantly lower than the remission
offered by both BPD (89 %) and RYGBP (77 %). This is
confirmed by another large-scale meta-analysis from China
on 7883 diabetic patients [12]. If we, in fact, consider the data,
available for 6373 patients, about the efficacy of different
surgical procedures, LRYGBP, SG, and LAGB provided a
T2DM remission rate of 74.4, 61.3, and 33 %, respectively.
Table 4 Clinical and
biochemical conditions in patients
at 12 months of follow-up
according to surgical procedure
MGB/OAGB (n=96) SG (n=110) p
BMI 33.1±6.6 35.9±5.9 <0.001
% BMI −30.9±8.93 −24.8±8.07 <0.001
EWL% 64.7±22.9 52.4±18.3 <0.001
FPG 104.0±19.6 122.2±38.6 <0.001
HbA1c 5.9±1.1 6.2±0.9 <0.001
Oral antidiabetic 7/96 + 23/110 +
Insulin 7/96 20/110
14/96 (14.6 %) 43/110 (39.1 %) <0.001
Remission 82/96 (85.4 %) 67/110 (60.9 %) <0.001
Total cholesterol 168.7±29.4 178.7±29.1 0.9
HDL cholesterol 52.4±17.3 51.6±10.5 0.7
LDL cholesterol 104.2±31.2 107.2±29.9 0.4
Triglycerides 141.6±56.7 140.9±51.4 0.9
Blood pressure
Max (range) 129.0±12.3 134.8±14.8 0.003
Min (range) 77.0±11.4 81.5±10.4 0.003
The p value reports the eventual statistical difference in patients assuming oral antidiabetic agents and/or insulin
60.9
85.4
Fig. 1 Remission rate from T2DM of patients who underwent MGB/
OAGB or SG
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Less is known about the metabolic efficacy of MGB/
OAGB. Lee, in 2011, investigated the metabolic role of this
procedure in a randomized controlled trial (RCT) involving 60
moderately obese diabetic patients [38]. The results showed a
higher efficacy of MGB/OAGB vs. SG both in terms of
weight loss and T2DM remission. These results are confirmed
in another multicenter Asian report in 2012 on 200moderately
obese patients [39]. Individuals who underwent gastric bypass
procedures (LRYGBP or MGB/OAGB) lost more weight and
reached a higher T2DM remission rate at 1 year, compared to
patients treated by restrictive procedures (SG or LAGB). The
efficacy of MGB/OAGB in providing diabetes remission is
confirmed in long-term studies as well. Lee reports a signifi-
cantly lower level of HbA1c at 5 years in patients who
underwent MGB/OAGB vs. SG in a RCT [40], while Guenzi
reported 82.5 % of diabetes control with HbA1c lower than
6.5 %, after a mean follow-up of 26 months, following MGB/
OAGB [41]. This is also confirmed in our Italian multicenter
experience, reporting a T2DM remission rate of 84.4 % at
5 years of follow-up [42]. Published evidence on large num-
bers seems, therefore, to allow some conclusions. The first one
is the higher efficacy of bypass procedures, when compared to
SG or LAGB, in inducing T2DM remission [3, 11, 12, 40], the
second being the significant positive effect on remission pro-
vided by short diabetes duration [11, 12, 43]. Again, it has to
be observed that the T2DM remission rate is negatively influ-
enced by both high preoperative HbA1c levels and insulin use






Fig. 2 Scatter plot of Pearson’s correlations between BMI and HbA1c
(a) and BMI and FPG changes (b) followingMGB/OAGB.Delta:mean±
SD at 12 months—baseline at time of surgery; HbA1c hemoglobin A1c,
BMI body mass index, FPG fasting plasma glucose, MGB/OAGB mini






Fig. 3 Scatter plot of Pearson’s correlations between BMI and HbA1c (a) and BMI and FPG changes (b) following SG. Delta: mean±SD at
12 months—baseline at time of surgery; HbA1c hemoglobin A1c, BMI body mass index, FPG fasting plasma glucose, SG sleeve gastrectomy
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these conclusions. Both FPG and HbA1c at 1 year are signif-
icantly lower in diabetic patients treated by MGB/OAGB
when compared to SG patients. Furthermore, the postopera-
tive consumption of insulin or oral antidiabetic agents resulted
to be significantly higher in this latter group as shown in
Table 4. At the same time, while diabetes duration longer than
10 years, high HbA1c levels, and consumption of insulin at
preoperative stage represented negative predictors; converse-
ly, the use of MGB/OAGB resulted as a positive predictor of
T2DM remission in a multivariate analysis.
The last question coming from published evidence is more
controversial. It is represented by the role played by BMI
changes in diabetes remission. In our study, we actually found
a bypass procedure as MGB/OAGB being more effective than
the SG in providing diabetes remission but, conversely, the
significantly higher BMI decrease offered by MGB/OAGB
does not allow us to define in which terms T2DM remission
is related to weight loss at 1 year. While some authoritative
series claims, in fact, the importance of BMI decrease in
reaching a significant and long-lasting T2DM remission [2, 3,
10, 29, 40], on the other hand, if we observe large numbers of
meta-analysis, this issue seems to lose relevance [8, 11, 12]
especially when moderately obese diabetic patients are consid-
ered [44]. This debatable issue has been validated byMingrone
as well, who recorded T2DM remission occurring before sig-
nificant weight loss [30]. Our finding seems to confirm those
hypotheses that diabetes remission may be independent from
weight loss and reinforces the concept that the type of surgery
may play a more relevant role. If we, in fact, consider, for both
MGB/OAGB and SG, the changes of FPG and HbA1c in re-
lation to BMI decrease, we did not find any significant corre-
lation at Pearson’s analysis as shown in Figs. 2 and 3.
Cardiovascular events are also reduced following bariatric
surgery. In this light, our review seems to confirm high-
volume long-term studies [45, 46]. If we, in fact, consider lipid
profile and blood pressure in our patients, we observe changes
in HDL, LDL, triglycerides, and systolic and diastolic pres-
sure, which are significant if we compare surgery to baseline
condition. Furthermore, MGB/OAGB provided a significant
improvement in blood pressure values, at univariate analysis,
when compared to SG. Interestingly, confirming a previous
smaller series from our group [47], no significant differences
were observed in the lipid profile by comparing MGB/OAGB
to SG at 1 year (Table 4).
To our knowledge this is the wider series reporting MGB/
OAGB outcome on T2DM patients; nevertheless, our study
presents some limitations. The first one is the retrospective
design of the study accompanied by a follow-up limited at
12 months. Secondly, given that some useful T2DM parame-
ters as HOMA and C-peptide levels in the past were not rou-
tinely evaluated in some participating centers, they were not
available for this study. Again, the variation in lipid profile
and blood pressure was considered only for patients known in
treatment with antihypertensive drugs or lipid-lowering
agents. Finally, a dropout rate approaching 15 % of patients
eligible for follow-up has been recorded.
In conclusion, according to our results at 1 year, both
MGB/OAGB and SG, in patients presenting a BMI >35 kg/
m2, provide significant weight loss and T2DM remission, al-
though, interestingly, this last result is unrelated to weight loss
for both techniques. In particular, MGB/OAGB, while offer-
ing a very acceptable surgical risk rate, outperforms signifi-
cantly SG in terms of BMI reduction, T2DM remission, and
reduction in blood pressure values. Following a multivariate
analysis, a long history of diabetes, accompanied by high
HbA1c levels and consumption of antidiabetic drugs, remains
to be a negative predictor of T2DM remission following sur-
gery; conversely, MGB/OAGB may be regarded as an inde-
pendent factor able to favor T2DM remission.
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